KR930019225A - 제암방법 및 제암제 - Google Patents

제암방법 및 제암제 Download PDF

Info

Publication number
KR930019225A
KR930019225A KR1019930003358A KR930003358A KR930019225A KR 930019225 A KR930019225 A KR 930019225A KR 1019930003358 A KR1019930003358 A KR 1019930003358A KR 930003358 A KR930003358 A KR 930003358A KR 930019225 A KR930019225 A KR 930019225A
Authority
KR
South Korea
Prior art keywords
anticancer
antigen
histocompatibility class
cancer
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019930003358A
Other languages
English (en)
Korean (ko)
Inventor
고우지 에가와
이찌에이 사또
Original Assignee
사토이찌에이
바이오 디펜스 인스티튜트 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사토이찌에이, 바이오 디펜스 인스티튜트 캄파니 리미티드 filed Critical 사토이찌에이
Publication of KR930019225A publication Critical patent/KR930019225A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019930003358A 1992-03-05 1993-03-05 제암방법 및 제암제 Withdrawn KR930019225A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4048840A JPH05246889A (ja) 1992-03-05 1992-03-05 制癌方法および制癌剤
JP4-48840 1992-03-05

Publications (1)

Publication Number Publication Date
KR930019225A true KR930019225A (ko) 1993-10-18

Family

ID=12814449

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930003358A Withdrawn KR930019225A (ko) 1992-03-05 1993-03-05 제암방법 및 제암제

Country Status (15)

Country Link
EP (1) EP0563627A2 (https=)
JP (1) JPH05246889A (https=)
KR (1) KR930019225A (https=)
CN (1) CN1079400A (https=)
AU (1) AU3398793A (https=)
BR (1) BR9300764A (https=)
CA (1) CA2090957A1 (https=)
CZ (1) CZ34293A3 (https=)
FI (1) FI930976A7 (https=)
HU (1) HUT67859A (https=)
IL (1) IL104944A0 (https=)
NO (1) NO930798L (https=)
NZ (1) NZ247057A (https=)
SK (1) SK15993A3 (https=)
ZA (1) ZA931558B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
IT1274592B (it) * 1994-08-05 1997-07-18 Angela Turiano Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
EP0937258A2 (en) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
CA2321222A1 (fr) * 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
FR2775189B1 (fr) * 1998-07-24 2001-06-08 Commissariat Energie Atomique Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1245675A1 (en) * 2001-03-28 2002-10-02 Kohji Egawa Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof
WO2004078137A2 (en) * 2003-03-04 2004-09-16 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung

Also Published As

Publication number Publication date
EP0563627A2 (en) 1993-10-06
FI930976L (fi) 1993-09-06
NO930798D0 (no) 1993-03-04
CN1079400A (zh) 1993-12-15
BR9300764A (pt) 1993-09-28
NO930798L (no) 1993-09-06
CZ34293A3 (en) 1994-01-19
AU3398793A (en) 1993-09-09
FI930976A7 (fi) 1993-09-06
NZ247057A (en) 1995-10-26
FI930976A0 (fi) 1993-03-04
CA2090957A1 (en) 1993-09-06
JPH05246889A (ja) 1993-09-24
EP0563627A3 (https=) 1994-04-27
IL104944A0 (en) 1993-07-08
HUT67859A (en) 1995-03-23
ZA931558B (en) 1993-09-27
SK15993A3 (en) 1993-10-06
HU9300612D0 (en) 1993-05-28

Similar Documents

Publication Publication Date Title
Lehner et al. Association between HLA-DR antigens and helper cell activity in the control of dental caries
Mehra et al. Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid
Kiessling et al. Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems.
Nakamura et al. Effect of IFN-γ on the immune response in vivo and on gene expression in vitro
Gery et al. Potentiation of the T-lymphocyte response to mitogens: II. the cellular source of potentiating mediator (s)
Handman et al. Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies
Gorczynski et al. Nonspecific and specific immuno-suppression in tumour-bearing mice by soluble immune complexes
Aune et al. Activation of a suppressor T-cell pathway by interferon.
Delfraissy et al. Primary in vitro antibody response from human peripheral blood lymphocytes
DE69634266D1 (de) Epitope von diphtheriatoxin
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
KR930019225A (ko) 제암방법 및 제암제
CA2078235A1 (en) Idiotypic vaccination against b cell lymphoma
AU2112288A (en) Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease
Elson et al. Fc receptors on mouse placenta and yolk sac cells
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
Shirakawa et al. Immunosuppressive factors from adult T-cell leukemia cells
Scavulli et al. Competition between concanavalin A-induced stimulatory and inhibitory effects in the in vitro immune response to antigen.
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
Stutman et al. Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice
WO1999017787A3 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
Attallah et al. Differential effects of interferon on the MHC expression of human lymphocytes: enhanced expression of HLA without effect on Ia
Hodge et al. Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF‐beta as an immunomodulatory component in plasma‐derived factor VIII concentrate
Henney et al. Natural killer cells. In vitro and in vivo
Damle et al. Activation of antigen-specific suppressor T lymphocytes in man involves dual recognition of self class I MHC molecules and Leu-4/T3-associated structures on the surface of inducer T lymphocytes.

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000